04 · 21 proprietary layers
Layer 10 of 21 · Tumour behaviour
RNA Expression & Signatures Expression patterns and signatures.
Why it's needed
What RNA expression information or signatures are available and relevant?
What it draws on
1 of 8 evidence domains.
What it produces
Expression and signature summaries and their evidence context.
Why it's essential
Layer 10 of 21.
1 · What it does
What RNA Expression & Signatures does
DNA shows which genes are altered; RNA shows which genes are being actively used. RNA data can support the detection of gene fusions and expression-based signatures. This layer is intended to summarise whatever RNA information the selected pathway provides.
2 · Scientific question
The question it addresses
What RNA expression information or signatures are available and relevant?
Intended function
Describe the RNA expression and signature analysis included in the validated workflow.
3 · Data inputs and required context
What it draws on
- 01 Molecular & genomic
RNA data, where the pathway generates them. Twin Blood as 'DNA and RNA together'.
4 · Scientific basis
The science behind it
Scientific basis
RNA sequencing and targeted RNA assays are used to detect fusion transcripts, splice variants and expression levels. Expression signatures depend on the assay and on how the data are normalised.
5 · Output and evidence sources
What it produces
Main output
Expression and signature summaries and their evidence context.
Output type
- Assay-derived finding. Reported from laboratory sequencing data, subject to assay scope and quality.
- Computational inference. Estimated by analysis of available data rather than measured directly.
6 · Why it\u2019s essential
How it powers the Twin
Supports fusion detection for AccessMatch and expression context for PhenoMap, ImmuneLens and the microenvironment layer.
Report section
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
Expression-level and fusion information, with the assay that produced it.
Doctor & Clinical Team8 · Dependencies and limitations
Limitations
- Twin Blood includes RNA; for other routes, RNA is included where the chosen assay supports it.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Expression findings state the assay and normalisation; routes without RNA show the layer as not applicable.
10 · Claim boundary
What this layer does not establish
Without RNA input, this layer produces no expression findings.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process